PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 2 Study Of PF-00232798 In HIV Positive Patients
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00495677
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Koeln, Germany
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00494091
- Locations
- ๐ฐ๐ท
Pfizer Investigational Site, Seoul, Korea, Republic of
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
Phase 3
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccineBiological: 13vPnC + TIV
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1185
- Registration Number
- NCT00492557
A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1028
- Registration Number
- NCT00488488
Observational Trial With Enbrel
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4945
- Registration Number
- NCT00488475
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Muenster, NRW, Germany
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients
Phase 2
Withdrawn
- Conditions
- Human Immunodeficiency Virus
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00488995
Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.
- First Posted Date
- 2007-06-11
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00484718
- Locations
- ๐บ๐ธ
VAPAHCS, Palo Alto, California, United States
๐บ๐ธStanford University, Stanford, California, United States
Study Investigating Rapamune For Post-Marketing Surveillance
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 209
- Registration Number
- NCT00484094
- Locations
- ๐ฐ๐ท
Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
๐ฐ๐ทYeungnam University Medical Center, Daegu, Korea, Republic of
A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee
Phase 2
Terminated
- Conditions
- Osteoarthritis
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT00483977
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Richmond, Virginia, United States
Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 183
- Registration Number
- NCT00484185
- Locations
- ๐ฐ๐ท
Pfizer Investigational Site, Seoul, Korea, Republic of
ยฉ Copyright 2025. All Rights Reserved by MedPath